One of the most common types of mutations in the dystrophin gene occurs when a piece of the code in the middle of the gene is missing or deleted. By skipping additional segments of the dystrophin code called exons, the deletion can shift from an out-of-frame deletion to an in-frame deletion. Typically, an in-frame deletion results in a smaller, but still functional, dystrophin protein. This shortened protein is expected to act in a similar way to normal dystrophin, and so relieve some symptoms of Duchenne and hopefully result in a milder presentation. Entrada’s ENTR-601-45 is an exon skipping therapy utilizing their Endosomal Escape Vehicle (EEV) technology to increase cellular uptake of oligonucleotide for those amenable to exon 45 skipping.
A Phase 1/2 trial is is not yet recruiting outside the US.
This program is sponsored by Entrada Therapeutics.
For information regarding current or upcoming clinical trials please visit our Explore Clinical Trials Page.
